Concordance	O
of	O
real	O
-	O
world	O
versus	O
conventional	O
progression	O
-	O
free	O
survival	O
from	O
a	O
phase	B-study_type
3	I-study_type
trial	I-study_type
of	O
endocrine	O
therapy	O
as	O
first	O
-	O
line	O
treatment	O
for	O
metastatic	O
breast	O
cancer	O
Concordance	O
of	O
real	O
-	O
world	O
versus	O
conventional	O
progression	O
-	O
free	O
survival	O
from	O
a	O
phase	B-study_type
3	I-study_type
trial	I-study_type
of	O
endocrine	O
therapy	O
as	O
first	O
-	O
line	O
treatment	O
for	O
metastatic	O
breast	O
cancer	O
April	O
21	O
,	O
2020	O
April	O
21	O
,	O
2020	O
CynthiaHuang	B-authors

Concordance	O
of	O
real	O
-	O
world	O
versus	O
conventional	O
progression	O
-	O
free	O
survival	O
from	O
a	O
phase	B-study_type
3	I-study_type
trial	I-study_type
of	O
endocrine	O
therapy	O
as	O
first	O
-	O
line	O
treatment	O
for	O
metastatic	O
breast	O
cancer	O

Received	O
:	O
January	O
31	O
,	O
2019	O
Accepted	O
:	O
December	O
15	O
,	O
2019	O
CynthiaHuang	B-authors
cynthia.huang@pfizer.com	O
Bartlett1	B-authors
☯	O
JackMardekian1	B-authors
☯	O
MatthewJamesCotter	B-authors
XinHuang	B-authors
ZheZhang1	B-authors
☯	O
ChristinaMParrinello	B-authors
Flatiron	O
Health	O
New	O
York	O
NY	O

Concordance	O
of	O
real	O
-	O
world	O
versus	O
conventional	O
progression	O
-	O
free	O
survival	O
from	O
a	O
phase	B-study_type
3	I-study_type
trial	I-study_type
of	O
endocrine	O
therapy	O
as	O
first	O
-	O
line	O
treatment	O
for	O
metastatic	O
breast	O
cancer	O

Received	O
:	O
January	O
31	O
,	O
2019	O
Accepted	O
:	O
December	O
15	O
,	O
2019	O
CynthiaHuang	B-authors
cynthia.huang@pfizer.com	O
Bartlett1	B-authors
☯	O
JackMardekian1	B-authors
☯	O
MatthewJamesCotter	B-authors
XinHuang	B-authors
ZheZhang1	B-authors
☯	O
ChristinaMParrinello	B-authors
Flatiron	O
Health	O
New	O
York	O
NY	O

Concordance	O
of	O
real	O
-	O
world	O
versus	O
conventional	O
progression	O
-	O
free	O
survival	O
from	O
a	O
phase	B-study_type
3	I-study_type
trial	I-study_type
of	O
endocrine	O
therapy	O
as	O
first	O
-	O
line	O
treatment	O
for	O
metastatic	O
breast	O
cancer	O
CynthiaHuang	B-authors

cynthia.huang@pfizer.com	O
CynthiaHuang	B-authors
Cynthia	B-authors
Huang	I-authors
cynthia.huang@pfizer.com	O
Bartlett1	B-authors
☯	O
Bartlett1	B-authors
☯	O
Bartlett	B-authors
1	O
☯	O
JackMardekian1	B-authors
☯	O
JackMardekian1	B-authors
☯	O
Jack	B-authors
Mardekian	I-authors
1	O
☯	O
MatthewJamesCotter	B-authors
MatthewJamesCotter	B-authors
Matthew	B-authors
James	I-authors
Cotter	I-authors
XinHuang	B-authors
XinHuang	B-authors
Xin	B-authors
Huang	I-authors
ZheZhang1	B-authors
☯	O
ZheZhang1	B-authors
☯	O
Zhe	B-authors
Zhang	I-authors
1	O
☯	O
ChristinaMParrinello	B-authors
Flatiron	O
Health	O
New	O
York	O
NY	O

0000	O
-	O
0002	O
-	O
9838	O
-	O
0544	O
ArielBulua	B-authors
Ariel	B-authors
Bulua	I-authors
0000	O
-	O
0002	O
-	O
9838	O
-	O
0544	O
2	O
☯	O
1	O
Pfizer	O
Inc	O
New	O
York	O
NY	O

UNITED	O
STATES	O
Medical	O
Center	O
University	O
of	O
Nebraska	O
UNITED	O
STATES	O
UNITED	O
STATES	O
Concordance	O
of	O
real	O
-	O
world	O
versus	O
conventional	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
from	O
a	O
phase	B-study_type
3	I-study_type
trial	I-study_type
of	O
endocrine	O
therapy	O
as	O
first	O
-	O
line	O
treatment	O
for	O
metastatic	O
breast	O
cancer	O
April	O
21	O
,	O
2020	O
April	O
21	O
,	O
2020	O
April	O
21	O
,	O
2020	O
10.1371	O
/	O
journal.pone.0227256	O
Received	O
:	O
January	O
31	O
,	O
2019	O
Accepted	O
:	O
December	O
15	O
,	O
2019	O

To	O
evaluate	O
the	O
relationship	O
between	O
real	O
-	O
world	O
and	O
clinical	O
trial	O
outcomes	O
in	O
oncology	O
,	O
it	O
is	O
critical	O
to	O
assess	O
the	O
comparability	O
of	O
the	O
data	O
derived	O
in	O
each	O
of	O
these	O
settings	O
while	O
minimizing	O
the	O
effect	O
of	O
confounding	O
due	O
to	O
differences	O
in	O
prognostically	O
important	O
variables	O
.	O
[	O
11,12	O
]	O
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
PFS	B-arm_efficacy_metric
and	O
response	O
rates	O
generated	O
using	O
real	O
-	O
world	O
data	O
reflecting	O
routine	O
clinical	O
care	O
with	O
outcomes	O
observed	O
in	O
a	O
traditional	O
RCT	O
.	O
To	O
achieve	O
this	O
goal	O
,	O
we	O
analyzed	O
data	O
from	O
a	O
curated	O
EHR	O
-	O
derived	O
real	O
-	O
world	O
dataset	O
to	O
compare	O
outcomes	O
in	O
a	O
cohort	O
of	O
women	O
with	O
hormone	O
-	O
receptor	O
positive	O
(	O
HR+	O
)	O
,	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-negative	O
(	O
HER2-	O
)	O
metastatic	O
breast	O
cancer	O
(	O
mBC	O
)	O
who	O
received	O
first	O
-	O
line	O
letrozole	O
therapy	O
in	O
a	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
setting	O
with	O
those	O
in	O
the	O
control	B-arm_description
arm	I-arm_description
of	O
the	O
phase	B-study_type
3	I-study_type
PALOMA-2	I-study_type
trial	I-study_type
.	O
[	O
13	O
]	O
An	O
inverse	O
probability	O
of	O
treatment	O
weighting	O
(	O
IPTW	O
)	O
approach	O
was	O
used	O
to	O
account	O
for	O
potential	O
baseline	O
differences	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
and	O
PALOMA-2	B-arm_description
cohorts	O
,	O
which	O
allowed	O
retrospective	O
evaluation	O
of	O
the	O
comparability	O
of	O
the	O
realworld	B-arm_description
and	O
traditional	O
RECIST	O
-	O
based	O
clinical	O
trial	O
endpoints	O
in	O
2	O
similar	O
cohorts	O
.	O
[	O
14][15][16	O
]	O
Design	O
and	O
methods	O

The	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
was	O
drawn	O
from	O
de	O
-	O
identified	O
patient	O
data	O
from	O
the	O
Flatiron	O
Health	O
database	O
,	O
a	O
longitudinal	O
,	O
demographically	O
and	O
geographically	O
diverse	O
database	O
derived	O
from	O
EHR	O
data	O
.	O
[	O
17	O
]	O
At	O
the	O
time	O
of	O
this	O
study	O
,	O
the	O
overall	O
database	O
encompassed	O
more	O
than	O
2000	O

Funding	O
:	O
These	O
analyses	O
and	O
the	O
studies	O
included	O
in	O
these	O
analyses	O
(	O
NCT01740427	O
)	O
were	O
sponsored	O
by	O
Pfizer	O
Inc.	O
The	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
data	O
used	O
are	O
derived	O
from	O
the	O
Flatiron	O
Health	O
Analytic	O
electronic	O
health	O
record	O
database	O
as	O
reported	O
in	O
the	O
manuscript	O
and	O
were	O
purchased	O
by	O
Pfizer	O
from	O
Flatiron	O
Health	O
Inc.	O
,	O
an	O
independent	O
subsidiary	O
of	O
the	O
Roche	O
Group	O
.	O
Editorial	O
and	O
medical	O
writing	O
support	O
was	O
provided	O
by	O
Catherine	O
Grillo	O
,	O
of	O
Complete	O
Healthcare	O
Communications	O
,	O
LLC	O
(	O
North	O
Wales	O
,	O
PA	O
)	O
,	O
a	O
CHC	O
Group	O
company	O
,	O
and	O
was	O
funded	O
by	O
Pfizer	O
.	O
The	O
authors	O
also	O
wish	O
to	O
thank	O
Amy	O
P.	O
Abernethy	O
,	O
MD	O
,	O
PhD	O
,	O
for	O
her	O
work	O
on	O
developing	O
this	O
manuscript	O
while	O
at	O
Flatiron	O
Health	O
Inc.	O
;	O
Dr.	O
Abernethy	O
's	O
participation	O
in	O
the	O
development	O
of	O
this	O
manuscript	O
occurred	O
prior	O
to	O
her	O
appointment	O
as	O
Principal	O
Deputy	O
Commissioner	O
of	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
.	O
Cynthia	B-authors
Huang	I-authors
Bartlett	I-authors
is	O
a	O
former	O
employee	O
of	O
Pfizer	O
Inc.	O
Jack	B-authors
Mardekian	I-authors
,	O
Matthew	B-authors
James	I-authors
Cotter	I-authors
,	O
Xin	B-authors
Huang	I-authors
and	O
Zhe	B-authors
Zhang	I-authors
are	O
employed	O
by	O
Pfizer	O
Inc.	O
Pfizer	O
Inc	O
provided	O
support	O
in	O
the	O
form	O
of	O
salaries	O
for	O
authors	O
CHB	O
,	O
JM	O
,	O
MJC	O
,	O
XH	O
and	O
ZZ	O
,	O
study	O
design	O
,	O
data	O
collection	O
,	O
and	O
data	O
analysis	O
.	O
The	O
interpretation	O
of	O
the	O
data	O
,	O
the	O
content	O
of	O
the	O
manuscript	O
,	O
and	O
the	O
decision	O
to	O
publish	O
were	O
at	O
the	O
discretion	O
of	O
the	O
authors	O
.	O
Christina	B-authors
M.	I-authors
Parrinello	I-authors
and	O
Ariel	B-authors
Bulua	I-authors
Bourla	I-authors
are	O
employed	O
by	O
Flatiron	O
Health	O
.	O
Flatiron	O
Health	O
provided	O
support	O
in	O
the	O
form	O
of	O
study	O
design	O
,	O
data	O
collection	O
and	O
management	O
,	O
and	O
salaries	O
for	O
authors	O
CMP	O
and	O
ABB	O
,	O
but	O
did	O
not	O
have	O
any	O
additional	O
role	O
in	O
the	O
data	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O

Competing	O
interests	O
:	O
I	O
have	O
read	O
the	O
journal	O
's	O
policy	O
and	O
wish	O
to	O
report	O
the	O
following	O
conflicts	O
:	O
Cynthia	B-authors
Huang	I-authors
Bartlett	I-authors
is	O
a	O
former	O
employee	O
of	O
and	O
owns	O
stock	O
in	O
Pfizer	O
Inc.	O
Jack	B-authors
Mardekian	I-authors
,	O
Matthew	B-authors
James	I-authors
Cotter	I-authors
,	O
Xin	B-authors
Huang	I-authors
,	O
and	O
Zhe	B-authors
Zhang	I-authors
are	O
employees	O
of	O
and	O
own	O
stock	O
in	O
Pfizer	O
Inc.	O
Christina	B-authors
M.	I-authors
Parrinello	I-authors
,	O
and	O
Ariel	B-authors
Bulua	I-authors
Bourla	I-authors
are	O
employees	O
of	O
Flatiron	O
Health	O
,	O
Inc.	O
,	O
which	O
is	O
an	O
independent	O
subsidiary	O
of	O
the	O
Roche	O
Group	O
,	O
and	O
which	O
received	O
funding	O
from	O
Pfizer	O
for	O
the	O
conduct	O
of	O
this	O
study	O
;	O
they	O
also	O
report	O
equity	O
ownership	O
in	O
Flatiron	O
Health	O
Inc.	O
All	O
authors	O
affirm	O
that	O
these	O
competing	O
interests	O
do	O
not	O
alter	O
our	O
adherence	O
to	O
PLOS	O
ONE	O
policies	O
on	O
sharing	O
data	O
and	O
materials	O
.	O

clinicians	O
at	O
approximately	O
775	O
sites	O
of	O
care	O
across	O
the	O
United	O
States	O
(	O
US	O
)	O
,	O
representing	O
1.7	O
million	O
patients	O
with	O
active	O
cancer	O
.	O
Data	O
for	O
this	O
study	O
were	O
derived	O
from	O
a	O
curated	O
subsample	O
of	O
patients	O
with	O
confirmed	O
mBC	O
.	O

The	O
Flatiron	O
real	O
-	O
world	O
dataset	O
is	O
covered	O
under	O
the	O
Health	O
Insurance	O
Portability	O
and	O
Accountability	O
Act	O
of	O
1996	O
(	O
HIPAA	O
)	O
through	O
Business	O
Associate	O
Agreements	O
with	O
every	O
provider	O
in	O
the	O
Flatiron	O
network	O
.	O
These	O
agreements	O
authorize	O
Flatiron	O
to	O
collect	O
and	O
de	O
-	O
identify	O
patient	O
-	O
level	O
structured	O
and	O
unstructured	O
data	O
to	O
create	O
de	O
-	O
identified	O
data	O
sets	O
for	O
research	O
purposes	O
.	O
Processed	O
data	O
are	O
de	O
-	O
identified	O
according	O
to	O
either	O
the	O
Safe	O
Harbor	O
or	O
Expert	O
Determination	O
method	O
as	O
outlined	O
in	O
HIPAA	O
Section	O
164.514(b	O
)	O
.	O
When	O
using	O
the	O
Expert	O
Determination	O
method	O
,	O
Flatiron	O
employs	O
a	O
third	O
-	O
party	O
expert	O
to	O
design	O
the	O
de	O
-	O
identification	O
methodology	O
and	O
certify	O
that	O
the	O
dataset	O
is	O
de	O
-	O
identified	O
.	O
Only	O
de	O
-	O
identified	O
data	O
is	O
delivered	O
to	O
clients	O
.	O
Institutional	O
Review	O
Board	O
(	O
IRB	O
)	O
approval	O
was	O
obtained	O
for	O
this	O
study	O
;	O
informed	O
consent	O
was	O
waived	O
by	O
the	O
IRB	O
as	O
the	O
study	O
was	O
retrospective	O
and	O
non	O
-	O
interventional	O
,	O
using	O
routinely	O
collected	O
data	O
.	O
Details	O
on	O
the	O
IRB	O
are	O
available	O
in	O
S1	O
Appendix	O
.	O

Data	O
were	O
derived	O
from	O
a	O
random	O
sampling	O
(	O
with	O
attrition	O
at	O
each	O
step	O
,	O
Fig	O
1	O
)	O
of	O
women	O
diagnosed	O
with	O
mBC	O
between	O
January	O
1	O
,	O
2011	O
,	O
and	O
September	O
30	O
,	O
2015	O
(	O
inclusive	O
)	O
,	O
regardless	O
of	O
menopausal	O
status	O
.	O
Data	O
provided	O
were	O
de	O
-	O
identified	O
and	O
provisions	O
were	O
in	O
place	O
to	O
prevent	O
re	O
-	O
identification	O
in	O
order	O
to	O
protect	O
patients	O
'	O
confidentiality	O
.	O
Eligibility	O
criteria	O
aligned	O
with	O
those	O
of	O
the	O
PALOMA-2	O
trial	O
and	O
included	O
documented	O
HR+	O
(	O
estrogen	O
receptor	O
-	O
positive	O
[	O
ER+	O
]	O
or	O
progesterone	O
receptor	O
-	O
positive	O
)	O
and	O
HER2-disease	O
at	O
any	O
point	O
before	O
or	O
�	O
60	O
days	O
following	O
mBC	O
diagnosis	O
,	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
(	O
ECOG	O
PS	O
)	O
score	O
<3	O
within	O
30	O
days	O
of	O
mBC	O
diagnosis	O
,	O
and	O
initiation	O
of	O
letrozole	B-arm_description
monotherapy	O
in	O
the	O
first	O
-	O
line	O
metastatic	O
setting	O
before	O
October	O
1	O
,	O
2015	O
.	O
Patients	O
who	O
had	O
received	O
previous	O
treatment	O
with	O
a	O
cyclin	O
-	O
dependent	O
kinase	O
4/6	O
inhibitor	O
or	O
who	O
had	O
another	O
primary	O
cancer	O
diagnosis	O
�	O
3	O
year	O
before	O
initiation	O
of	O
letrozole	B-arm_description
monotherapy	O
were	O
excluded	O
.	O

The	O
RCT	O
cohort	O
comprised	O
women	O
from	O
the	O
control	B-arm_description
arm	I-arm_description
of	O
the	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
international	O
,	O
multicenter	O
,	O
phase	O
3	O
PALOMA-2	O
study	O
(	O
NCT01740427	O
)	O
(	O
Fig	O
1	O
)	O
.	O
The	O
study	O
was	O
approved	O
by	O
an	O
IRB	O
or	O
equivalent	O
ethics	O
committee	O
at	O
each	O
participating	O
site	O
,	O
and	O
all	O
patients	O
provided	O
written	O
informed	O
consent	O
before	O
enrollment	O
.	O
Details	O
on	O
participating	O
IRBs	O
/	O
ethics	O
committees	O
are	O
available	O
in	O
S1	O
Appendix	O
.	O
The	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
Good	O
Clinical	O
Practice	O
guidelines	O
and	O
the	O
provisions	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Eligible	O
patients	O
were	O
postmenopausal	O
women	O
aged	O
�	O
18	O
years	O
with	O
ER+/	O
HER2-advanced	O
breast	O
cancer	O
who	O
had	O
not	O
received	O
previous	O
endocrine	O
therapy	O
for	O
advanced	O
disease	O
.	O
Inclusion	O
criteria	O
included	O
postmenopausal	O
status	O
defined	O
as	O
previous	O
bilateral	O
surgical	O
oophorectomy	O
,	O
spontaneous	O
cessation	O
of	O
regular	O
menses	O
for	O
12	O
consecutive	O
months	O
,	O
or	O
folliclestimulating	O
hormone	O
and	O
estradiol	O
blood	O
levels	O
in	O
the	O
respective	O
postmenopausal	O
ranges	O
;	O
adequate	O
organ	O
function	O
;	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0−2	O
;	O
and	O
measurable	O
disease	O
as	O
defined	O
per	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
(	O
version	O
1.1	O
)	O
.	O
Exclusion	O
criteria	O
included	O
HER2	O
+	O
tumors	O
;	O
advanced	O
,	O
symptomatic	O
,	O
visceral	O
spread	O
at	O
risk	O
of	O
life	O
-	O
threatening	O
complications	O
;	O
previous	O
neoadjuvant	O
or	O
adjuvant	O
treatment	O
with	O
a	O
nonsteroidal	O
aromatase	O
inhibitor	O
with	O
disease	O
recurrence	O
while	O
on	O
or	O
within	O
12	O
months	O
of	O
completing	O
treatment	O
;	O
and	O
previous	O
cyclin	O
-	O
dependent	O
kinase	O
4/6	O
inhibitor	O
treatment	O
.	O
[	O
13	O
]	O

In	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
,	O
patients	O
were	O
treated	O
with	O
letrozole	B-arm_description
monotherapy	O
per	O
approved	O
labeling	O
and	O
treating	O
physicians	O
'	O
clinical	O
judgment	O
.	O
In	O
the	O
RCT	B-arm_description
cohort	I-arm_description
,	O
women	O
received	O
letrozole	B-arm_description
(	O
2.5	B-arm_dosage
mg	I-arm_dosage
once	I-arm_dosage
daily	I-arm_dosage
,	I-arm_dosage
administered	I-arm_dosage
orally	I-arm_dosage
)	O
plus	O
placebo	B-arm_description
per	O
the	O
PALOMA-2	B-study_type
study	I-study_type
protocol	O
.	O
[	O
13	O
]	O

For	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
,	O
tumor	O
burden	O
was	O
assessed	O
during	O
routine	O
clinical	O
visits	O
for	O
patients	O
with	O
HR+/HER2−	O
mBC	O
.	O
[	O
9,18	O
]	O
Tumor	O
burden	O
assessments	O
were	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physician	O
and	O
formalized	O
RECIST	O
methodology	O
was	O
not	O
generally	O
employed	O
.	O
Structured	O
and	O
unstructured	O
patient	O
-	O
level	O
data	O
were	O
extracted	O
from	O
the	O
EHR	O
using	O
Flatiron	O
Health	O
's	O
proprietary	O
technology	O
-	O
enabled	O
abstraction	O
platform	O
,	O
an	O
electronic	O
interface	O
mimicking	O
a	O
case	O
report	O
form	O
with	O
centralized	O
management	O
and	O
quality	O
controls	O
.	O
This	O
layer	O
of	O
technology	O
facilitates	O
document	O
classification	O
and	O
visual	O
organization	O
,	O
text	O
search	O
within	O
documents	O
,	O
and	O
selective	O
presentation	O
of	O
relevant	O
documents	O
to	O
trained	O
data	O
abstractors	O
(	O
clinical	O
oncology	O
nurses	O
and	O
tumor	O
registrars	O
)	O
.	O
Structured	O
data	O
such	O
as	O
diagnoses	O
,	O
lab	O
values	O
,	O
and	O
medication	O
administrations	O
were	O
mapped	O
to	O
a	O
common	O
terminology	O
and	O
unstructured	O
data	O
(	O
eg	O
,	O
physician	O
notes	O
,	O
lab	O
/	O
radiology	O
reports	O
)	O
underwent	O
manual	O
review	O
[	O
19	O
]	O
.	O
All	O
abstractors	O
received	O
training	O
in	O
the	O
use	O
of	O
the	O
platform	O
as	O
well	O
as	O
indication	O
-	O
specific	O
training	O
(	O
operating	O
procedures	O
,	O
best	O
practice	O
guidelines	O
)	O
prior	O
to	O
beginning	O
the	O
abstraction	O
process	O
.	O

Inverse	O
probability	O
of	O
treatment	O
weighting	O
was	O
used	O
to	O
adjust	O
analyses	O
for	O
differences	O
in	O
observed	O
potential	O
confounders	O
between	O
the	O
2	O
study	O
cohorts	O
.	O
[	O
16,20,21	O
]	O
The	O
IPTW	O
process	O
modifies	O
the	O
patient	O
counts	O
according	O
to	O
differences	O
in	O
unweighted	O
baseline	O
characteristics	O
.	O

Propensity	O
scores	O
were	O
generated	O
using	O
a	O
multivariable	O
logistic	O
model	O
executed	O
on	O
data	O
from	O
107	O
real	O
-	O
world	O
patients	O
and	O
222	O
PALOMA-2	O
patients	O
.	O
Study	O
origin	O
(	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
or	O
PALOMA-2	O
)	O
was	O
used	O
as	O
an	O
outcome	O
and	O
potential	O
baseline	O
confounders	O
were	O
included	O
as	O
covariates	O
,	O
having	O
been	O
selected	O
based	O
on	O
the	O
authors	O
'	O
clinical	O
judgment	O
.	O
Covariates	O
included	O
were	O
age	O
,	O
race	O
,	O
disease	O
stage	O
at	O
diagnosis	O
(	O
I	O
-	O
IV	O
or	O
unrecorded	O
/	O
unknown	O
)	O
,	O
ECOG	O
PS	O
score	O
,	O
number	O
of	O
disease	O
sites	O
at	O
diagnosis	O
(	O
1	O
,	O
2	O
,	O
�	O
3	O
)	O
,	O
and	O
bone	O
-	O
only	O
metastases	O
.	O
In	O
order	O
to	O
balance	O
the	O
2	O
study	O
cohorts	O
for	O
duration	O
of	O
follow	O
-	O
up	O
,	O
the	O
propensity	O
score	O
model	O
also	O
included	O
potential	O
follow	O
-	O
up	O
,	O
a	O
baseline	O
measure	O
defined	O
as	O
the	O
number	O
of	O
months	O
from	O
a	O
patient	O
's	O
start	O
of	O
treatment	O
date	O
to	O
the	O
study	O
cutoff	O
:	O
September	O
30	O
,	O
2016	O
for	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
and	O
February	O
26	O
,	O
2016	O
for	O
PALOMA-2	O
.	O

Inverse	O
probability	O
of	O
treatment	O
weights	O
were	O
then	O
generated	O
for	O
each	O
patient	O
by	O
inverting	O
their	O
propensity	O
score	O
and	O
stabilizing	O
the	O
score	O
to	O
reduce	O
influences	O
from	O
large	O
weights	O
(	O
small	O
propensity	O
scores	O
)	O
by	O
multiplying	O
the	O
inverted	O
propensity	O
score	O
by	O
107/329	O
for	O
Flatiron	O
patients	O
and	O
222/329	O
for	O
PALOMA-2	O
patients	O
.	O
The	O
balance	O
in	O
prognostically	O
important	O
baseline	O
characteristics	O
was	O
assessed	O
using	O
a	O
standardized	O
differences	O
approach	O
,	O
with	O
values	O
�	O
0.10	O
indicating	O
a	O
non	O
-	O
negligible	O
imbalance	O
.	O

The	O
duration	O
of	O
first	O
line	O
letrozole	B-arm_description
therapy	O
was	O
abstracted	O
using	O
Flatiron	O
business	O
rules	O
applied	O
to	O
patient	O
EHRs	O
for	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
.	O
For	O
the	O
PALOMA-2	O
cohort	O
,	O
the	O
duration	O
of	O
treatment	O
was	O
obtained	O
from	O
information	O
recorded	O
in	O
the	O
data	O
collection	O
tool	O
used	O
in	O
the	O
study	O
.	O

The	O
Kaplan	O
-	O
Meier	O
method	O
was	O
used	O
to	O
estimate	O
median	B-arm_efficacy_metric
rwPFS	I-arm_efficacy_metric
and	O
RECIST	B-arm_efficacy_metric
-	I-arm_efficacy_metric
based	I-arm_efficacy_metric
PFS	B-arm_efficacy_metric
for	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
and	O
PALOMA-2	O
cohorts	O
,	O
respectively	O
.	O
Hazard	O
ratios	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
were	O
computed	O
using	O
weighted	O
Cox	O
proportional	O
hazards	O
analysis	O
with	O
IPTW	O
adjustment	O
.	O
A	O
2-sided	O
p	O
<	O
0.05	O
was	O
considered	O
significant	O
.	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SAS	O
v.9.4	O
.	O

Between	O
January	O
1	O
,	O
2011	O
,	O
and	O
September	O
30	O
,	O
2015	O
(	O
data	O
cutoff	O
,	O
September	O
30	O
,	O
2016	O
)	O
,	O
107	O
women	O
initiated	O
letrozole	B-arm_description
monotherapy	O
and	O
met	O
the	O
eligibility	O
criteria	O
for	O
inclusion	O
in	O
the	O

unadjusted	O
real	O
-	O
world	O
cohort	O
(	O
Fig	O
1	O
)	O
.	O
In	O
PALOMA-2	O
,	O
222	O
patients	O
were	O
randomized	O
to	O
treatment	O
with	O
letrozole	B-arm_description
plus	O
placebo	B-arm_description
between	O
February	O
2013	O
and	O
July	O
2014	O
(	O
cutoff	O
date	O
for	O
final	O
analysis	O
,	O
February	O
26	O
,	O
2016	O
)	O
and	O
were	O
included	O
in	O
the	O
unadjusted	O
RCT	O
cohort	O
(	O
Table	O
3	O
)	O
.	O
The	O
number	O
of	O
patients	O
in	O
each	O
cohort	O
were	O
modified	O
by	O
IPTW	O
according	O
to	O
differences	O
in	O
unweighted	O
baseline	O
characteristics	O
.	O
Rounding	O
to	O
the	O
nearest	O
whole	O
number	O
,	O
the	O
IPTWadjusted	O
number	O
was	O
116	O
for	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
and	O
207	O
for	O
the	O
RCT	O
cohort	O
(	O
Table	O
4	O
)	O
.	O

Unweighted	O
,	O
unadjusted	O
demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
2	O
cohorts	O
were	O
broadly	O
comparable	O
,	O
although	O
patients	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
were	O
older	O
(	O
mean	O
age	O
68.6	O
vs	O
60.6	O
y	O
in	O
PALOMA-2	B-arm_description
)	O
,	O
more	O
racially	O
diverse	O
,	O
had	O
poorer	O
performance	O
status	O
(	O
12.1	O
%	O
vs	O
1.4	O
%	O
with	O
ECOG	O
PS	O
2	O
)	O
,	O
and	O
were	O
more	O
likely	O
to	O
have	O
stage	O
IV	O
disease	O
(	O
39.3	O
%	O
vs	O
32.4	O
%	O
)	O
and	O
boneonly	O
metastases	O
(	O
29.9	O
%	O
vs	O
21.6	O
%	O
)	O
at	O
diagnosis	O
(	O
Table	O
3	O
)	O
.	O
Of	O
note	O
,	O
two	O
patients	O
with	O
confirmed	O
HER2−	O
disease	O
prior	O
to	O
their	O
metastatic	O
diagnosis	O
had	O
equivocal	O
results	O
when	O
tested	O
closer	O
to	O
the	O
metastatic	O
diagnosis	O
date	O
.	O
In	O
both	O
cases	O
the	O
most	O
recent	O
result	O
was	O
documented	O
.	O

Data	O
abstractors	O
were	O
instructed	O
to	O
record	O
menopausal	O
status	O
only	O
when	O
it	O
was	O
explicitly	O
stated	O
in	O
the	O
patient	O
's	O
chart	O
.	O
As	O
a	O
result	O
,	O
more	O
than	O
one	O
-	O
third	O
of	O
patients	O
were	O
classified	O
as	O
"	O
unknown	O
.	O
"	O
As	O
all	O
but	O
1	O
of	O
these	O
patients	O
-	O
a	O
54	O
year	O
old	O
-	O
were	O
over	O
the	O
age	O
of	O
60	O
,	O
these	O
patients	O
were	O
retained	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
dataset	O
(	O
Table	O
3	O
)	O
.	O
Five	O
patients	O
classified	O
as	O
"	O
premenopausal	O
"	O
were	O
also	O
retained	O
.	O
Because	O
letrozole	B-arm_description
is	O
specifically	O
contraindicated	O
in	O
women	O
of	O
premenopausal	O
status	O
it	O
could	O
reasonably	O
be	O
inferred	O
that	O
these	O
patients	O
met	O
the	O
criteria	O
for	O
medically	O
confirmed	O
postmenopausal	O
status	O
or	O
were	O
in	O
medically	O
-	O
induced	O
menopause	O
as	O
a	O
result	O
of	O
ovarian	O
suppression	O
per	O
current	O
treatment	O
guidelines	O
and	O
standard	O
practice	O
.	O

After	O
IPTW	O
,	O
standardized	O
differences	O
were	O
reduced	O
for	O
all	O
baseline	O
demographic	O
and	O
clinical	O
variables	O
of	O
interest	O
.	O
Standardized	O
differences	O
were	O
<	O
0.10	O
for	O
prognostically	O
important	O
variables	O
including	O
age	O
,	O
ECOG	O
PS	O
,	O
disease	O
stage	O
III	O
or	O
IV	O
,	O
bone	O
-	O
only	O
metastases	O
,	O
and	O
potential	O
follow	O
-	O
up	O
(	O
Table	O
4	O
)	O
.	O
Standardized	O
differences	O
for	O
disease	O
stage	O
I	O
and	O
II	O
were	O
<	O
0.20	O
(	O
Table	O
4	O
)	O
.	O

Using	O
unadjusted	O
and	O
unweighted	O
patient	O
data	O
for	O
the	O
2	O
cohorts	O
,	O
median	B-arm_efficacy_metric
rwPFS	I-arm_efficacy_metric
was	O
18.7	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
14.6	I-arm_efficacy_results
-	I-arm_efficacy_results
24.1	I-arm_efficacy_results
)	I-arm_efficacy_results
for	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
patients	O
and	O
PFS	B-arm_efficacy_metric
was	O
14.5	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
12.9	I-arm_efficacy_results
-	I-arm_efficacy_results
17.1	I-arm_efficacy_results
)	I-arm_efficacy_results
for	O
PALOMA-2	B-arm_description
patients	O
(	B-arm_efficacy_results
hazard	I-arm_efficacy_results
ratio	I-arm_efficacy_results
,	I-arm_efficacy_results
1.38	I-arm_efficacy_results
[	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
1.00	I-arm_efficacy_results
-	I-arm_efficacy_results
1.91	I-arm_efficacy_results
]	I-arm_efficacy_results
)	I-arm_efficacy_results
;	I-arm_efficacy_results
Fig	I-arm_efficacy_results
2A	I-arm_efficacy_results
)	I-arm_efficacy_results
.	O
Median	B-arm_efficacy_metric
rwPFS	I-arm_efficacy_metric
was	O
longer	O
than	O
PFS	B-arm_efficacy_metric
in	O
the	O
PALOMA-2	B-arm_description
cohort	O
,	O
potentially	O
reflecting	O
the	O
higher	O
proportion	O
of	O
patients	O
with	O
bone	O
-	O
only	O
disease	O
in	O
this	O
group	O
.	O
Following	O
IPTW	O
adjustment	O
,	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
similar	O
in	O
both	O
cohorts	O
:	O
18.4	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
12.8	I-arm_efficacy_results
-	I-arm_efficacy_results
23.3	I-arm_efficacy_results
)	I-arm_efficacy_results
for	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
group	O
and	O
16.6	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
13.7	I-arm_efficacy_results
-	I-arm_efficacy_results
22.2	I-arm_efficacy_results
)	I-arm_efficacy_results
for	O
the	O
PALOMA-2	B-arm_description
group	O
(	O
Fig	O
2B	O
)	O
.	O
The	O
hazard	B-arm_efficacy_results
ratio	I-arm_efficacy_results
using	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
data	O
as	O
reference	O
was	O
1.04	B-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
0.69	I-arm_efficacy_results
-	I-arm_efficacy_results
1.56	I-arm_efficacy_results
)	I-arm_efficacy_results
.	I-arm_efficacy_results

The	O
unweighted	O
,	O
unadjusted	O
mean	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
)	O
duration	O
of	O
first	O
-	O
line	O
letrozole	B-arm_description
treatment	O
was	O
slightly	O
longer	O
among	O
patients	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
than	O
in	O
the	O
PALOMA-2	B-arm_description
cohort	O
:	O
17.1	O
months	O
(	O
13.0	O
)	O
and	O
14.0	O
months	O
(	O
8.9	O
)	O
,	O
respectively	O
,	O
standardized	O
difference	O
,	O

0.2810	O
.	O
After	O
IPTW	O
-	O
adjustment	O
,	O
mean	O
(	O
SD	O
)	O
duration	O
of	O
treatment	O
was	O
13.3	O
months	O
(	O
11.1	O
)	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
and	O
14.6	O
months	O
(	O
8.9	O
)	O
in	O
the	O
PALOMA-2	B-arm_description
group	O
,	O
with	O
a	O
reduction	O
in	O
standardized	O
difference	O
to	O
0.1242	O
(	O
Table	O
5	O
)	O
.	O
Discontinuations	O
due	O
to	O
treatment	O
-	O
related	O
adverse	O
events	O
or	O
toxicity	O
were	O
relatively	O
low	O
,	O
and	O
were	O
reported	O
more	O
frequently	O
among	O
patients	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
than	O
in	O
the	O
PALOMA-2	B-arm_description
cohort	O
(	O
6.5	O
%	O
and	O
4.1	O
%	O
,	O
respectively	O
)	O
(	O
Table	O
6	O
)	O
.	O

odds	O
ratio	O
:	O
0.92	O
[	O
95	O
%	O
CI	O
,	O
0.56	O
-	O
1.53	O
]	O
;	O
2-sided	O
P	O
=	O
.83	O
)	O
.	O
No	O
significant	O
difference	O
was	O
observed	O
between	O
rwRR	O
and	O
ORR	O
in	O
IPTW	O
adjusted	O
comparisons	O
:	O
41.8	O
%	O
and	O
39.4	O
%	O
,	O
respectively	O
(	O
odds	O
https://doi.org/10.1371/journal.pone.0227256.g002	O

ratio	O
:	O
0.91	O
[	O
95	O
%	O
CI	O
,	O
0.57	O
-	O
1.44	O
]	O
;	O
2-sided	O
P	O
=	O
.68	O
;	O
Fig	O
3A	O
)	O
.	O
Complete	O
tumor	O
response	O
was	O
more	O
frequently	O
reported	O
in	O
the	O
unadjusted	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
(	O
11.2	O
%	O
)	O
than	O
the	O
unadjusted	O
PALOMA-2	B-arm_description
group	O
(	O
2.3	O
%	O
)	O
(	O
Fig	O
3B	O
)	O
.	O
Of	O
note	O
,	O
22.4	O
%	O
of	O
patients	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
had	O
no	O
tumor	O
assessments	O
recorded	O
during	O
a	O
mean	O
5.8	O
months	O
of	O
first	O
line	O
therapy	O
.	O

disease	O
.	O
[	O
22,23]-in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
.	O
The	O
between	O
-	O
groups	O
difference	O
was	O
substantially	O
reduced	O
following	O
IPTW	O
adjustment	O
(	O
HR	O
=	O
1.04	O
;	O
95	O
%	O
CI	O
0.69	O
-	O
1.56	O
)	O
.	O

In	O
addition	O
,	O
in	O
contrast	O
to	O
the	O
global	O
PALOMA-2	B-arm_description
study	O
,	O
patients	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
are	O
all	O
from	O
the	O
US	O
and	O
receive	O
care	O
in	O
routine	O
clinical	O
settings	O
,	O
which	O
may	O
have	O
contributed	O
to	O
the	O
observed	O
differences	O
in	O
the	O
frequency	O
of	O
tumor	O
assessments	O
.	O
The	O
PALOMA-2	B-arm_description
protocol	O
specified	O
that	O
tumor	O
assessments	O
be	O
conducted	O
every	O
12	O
weeks	O
,	O
while	O
in	O
the	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
cohort	O
scans	O
were	O
ordered	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physician	O
.	O
It	O
is	O
noteworthy	O
that	O
12	O
of	O
the	O
patients	O
without	O
tumor	O
assessments	O
had	O
durations	O
of	O
treatment	O
longer	O
than	O
12	O
weeks	O
.	O

Despite	O
these	O
limitations	O
,	O
this	O
analysis	O
increases	O
confidence	O
that	O
data	O
from	O
real	O
-	O
world	O
health	O
care	O
databases	O
can	O
be	O
used	O
to	O
match	O
the	O
populations	O
of	O
randomized	O
clinical	O
trials	O
and	O
to	O
assess	O
key	O
outcomes	O
in	O
clinical	O
practice	O
settings	O
.	O
Although	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
study	O
of	O
its	O
kind	O
in	O
oncology	O
,	O
a	O
similar	O
analysis	O
of	O
data	O
from	O
a	O
large	O
health	O
care	O
database	O
successfully	O
mirrored	O
the	O
composite	O
endpoints	O
of	O
the	O
pivotal	O
ONTARGET	O
trial	O
of	O
the	O
angiotensin	O
receptor	O
blocker	O
telmisartan	O
.	O
[	O
24	O
]	O
The	O
analysis	O
of	O
data	O
from	O
more	O
than	O
50,000	O
patients	O
took	O
approximately	O
12	O
weeks	O
at	O
a	O
fraction	O
of	O
the	O
cost	O
of	O
the	O
pivotal	O
trial	O
.	O
[	O
24	O
]	O
Deriving	O
endpoints	O
in	O
the	O
oncology	O
setting	O
is	O
admittedly	O
a	O
more	O
labor	O
-	O
intensive	O
task	O
,	O
requiring	O
manual	O
review	O
of	O
unstructured	O
chart	O
elements	O
(	O
eg	O
,	O
clinician	O
notes	O
,	O
radiology	O
reports	O
)	O
to	O
arrive	O
at	O
high	O
quality	O
clinical	O
outcome	O
data	O
.	O
Enhancing	O
the	O
interoperability	O
of	O
EHRs	O
and	O
improving	O
the	O
capture	O
of	O
outcomes	O
data	O
are	O
core	O
goals	O
of	O
regulatory	O
and	O
private	O
sector	O
efforts	O
to	O
promote	O
meaningful	O
use	O
of	O
health	O
information	O
technology	O
(	O
HIT	O
)	O
.	O
[	O
25	O
]	O
Modifying	O
EHRs	O
to	O
include	O
structured	O
fields	O
that	O
capture	O
progression	O
and	O
response	O
and	O
training	O
clinicians	O
to	O
enter	O
relevant	O
data	O
into	O
the	O
correct	O
fields	O
may	O
provide	O
an	O
easier	O
path	O
to	O
capturing	O
outcome	O
measures	O
in	O
oncology	O
clinical	O
practice	O
settings	O
,	O
and	O
facilitate	O
both	O
retrospective	O
and	O
prospective	O
studies	O
of	O
real	O
-	O
world	O
outcomes	O
.	O
Such	O
an	O
effort	O
would	O
require	O
the	O
coordinated	O
efforts	O
of	O
multiple	O
stakeholders	O
to	O
provide	O
the	O
necessary	O
HIT	O
framework	O
,	O
education	O
,	O
and	O
support	O
to	O
physicians	O
and	O
allied	O
health	O
professionals	O
.	O

This	O
study	O
is	O
a	O
preliminary	O
but	O
important	O
step	O
in	O
showing	O
that	O
clinically	O
meaningful	O
information	O
can	O
be	O
derived	O
from	O
the	O
assessment	O
of	O
rwPFS	B-arm_efficacy_metric
and	O
rwRR	O
based	O
on	O
EHR	O
data	O
abstraction	O
when	O
proper	O
quality	O
controls	O
and	O
analytic	O
methods	O
are	O
incorporated	O
.	O
Although	O
limited	O
to	O
patients	O
with	O
mBC	O
,	O
the	O
current	O
study	O
lays	O
the	O
groundwork	O
for	O
additional	O
analyses	O
that	O
could	O
be	O
used	O
to	O
investigate	O
treatment	O
effects	O
using	O
real	O
-	O
world	O
data	O
in	O
other	O
malignancies	O
.	O
With	O
further	O
validation	O
,	O
real	O
-	O
world	O
data	O
may	O
help	O
to	O
modernize	O
the	O
clinical	O
trial	O
landscape	O
and	O
enhance	O
the	O
design	O
of	O
prospective	O
real	O
-	O
world	O
randomized	O
studies	O
.	O
for	O
HR+/HER2-mBC	O
.	O
CI	O
,	O
confidence	O
interval	O
;	O
HER2-	O
,	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-negative	O
;	O
HR+	O
,	O
hormone	O
-	O
receptor	O
positive	O
;	O
IPTW	O
,	O
inverse	O
probability	O
of	O
treatment	O
weighting	O
;	O
mBC	O
,	O
metastatic	O
breast	O
cancer	O
;	O
RWD	O
,	O
real	B-arm_description
-	I-arm_description
world	I-arm_description
data	O
.	O
a	O
RWD	O
as	O
reference	O
.	O